Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
6000 participants
OBSERVATIONAL
2018-11-14
2027-11-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
REALYSA is a platform perfectly set up to
* Study prognostic factors using integrated epidemiological and biological data (genetics), to better characterize the determinants of refractoriness and relapse in patients with lymphoma, to follow the growing number of survivors and describe median to long-term sequela, second cancer, quality of life (QoL)…
* Document treatment effectiveness in real life and observance
* Address socio-economical questions
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
NCT06830759
Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?
NCT03681938
Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia
NCT02520895
Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia
NCT05832125
BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.
NCT06424379
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All enrolled patients
All patient who signed the consent form for participation to the study
Real-life epidemiological platform of lymphoma in France
The REALYSA database will be described with the following characteristics:
* Number of patients included per month in total and according to subtype of lymphoma
* Number of patients in each region in total and according to subtype of lymphoma
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Real-life epidemiological platform of lymphoma in France
The REALYSA database will be described with the following characteristics:
* Number of patients included per month in total and according to subtype of lymphoma
* Number of patients in each region in total and according to subtype of lymphoma
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged over 18 at the time of inclusion
* Diagnosed with lymphoma in the last 6 months (180 days)
* Lymphoma subtype belonging to at least one of the 7 histological subtypes: diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt lymphoma
Exclusion Criteria
* Documented HIV infection
* Any other lymphoma subtype not included in the list in Appendix 1. Of note, are excluded:
* Chronic lymphocytic leukemia/small lymphocytic lymphoma
* Hairy cell leukemia and variant
* Lymphoplasmacytic lymphoma
* Waldenström macroglobulinemia
* Primary DLBCL of the central nervous system (CNS)
* T-cell large granular lymphocytic leukemia
* Chronic lymphoproliferative disorder of NK cells
* Mycosis fungoides
* Sézary syndrome
* Primary cutaneous T cell lymphomas (mainly diagnosed and treated by dermatologists)
* Post-transplant lymphoproliferative disorders (PTLD)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Lymphoma Academic Research Organisation
OTHER
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hervé Ghesquières, MD
Role: STUDY_DIRECTOR
Hospices Civils de Lyon
Alain Monnereau, MD
Role: STUDY_DIRECTOR
Université de Bordeaux : Inserm
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Unité d'Hématologie Clinique, CH D'ARRAS
Arras, , France
Service d'Hématologie, CHU Jean Minjoz
Besançon, , France
Service d'Onco-radiolothérapie, Polyclinique Bordeaux Nord Aquitaine
Bordeaux, , France
Institut Bergonié
Bordeaux, , France
Centre Hospitalier Pierre Oudot
Bourgoin, , France
Service d'Hématologie, Institut d'Hématologie de Basse Normandie
Caen, , France
METROPOLE SAVOIE - SITE CHAMBERY, place Lucien Biset,
Chambéry, , France
Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Estaing, CHU de Clermont-Ferrand
Clermont-Ferrand, , France
Unité Hémopathies Lymphoïdes, Hôpital Henri Mondor
Créteil, , France
CHU Francois MITTERRAND
Dijon, , France
Service Hématologie, Centre Hospitalier de Dunkerque
Dunkirk, , France
Service Oncologie médicale, Groupe Hospitalier Mutualiste de Grenoble, Institut Daniel Hollard,
Grenoble, , France
CHD Vendée
La Roche-sur-Yon, , France
Service d'Hématologie Clinique, Centre Hospitalier Universitaire Michallon
La Tronche, , France
Clinique Victor Hugo
Le Mans, , France
Centre hospitalier Libourne
Libourne, , France
Service Oncologie médicale, HOPITAL SAINT VINCENT-DE-PAUL
Lille, , France
Service des maladies du sang, Hôpital Claude Huriez, CHRU de Lille
Lille, , France
Service Hématologie Clinique et Thérapie Cellulaire, CHU DE LIMOGES - HOPITAL DUPUYTREN,
Limoges, , France
Département d'Hématologie et Oncologie, Centre Léon Bérard
Lyon, , France
Département d'Hématologie Clinique, Hôpital Saint-Eloi,
Montpellier, , France
Service Hématologie, GH REGION MULHOUSE ET SUD ALSACE - HOPITAL EMILE MULLER,
Mulhouse, , France
Service d'Hématologie clinique, Centre Hospitalier Universitaire de Nantes
Nantes, , France
Centre Hospitalier de Niort
Niort, , France
Service Hématologie, Hôpital St Louis
Paris, , France
CHU Haut-Lévêque
Pessac, , France
Centre Hospitalier Lyon Sud
Pierre-Bénite, , France
Service d'Hématologie et Thérapie Cellulaire, Centre Hospitalier Universitaire de Poitiers
Poitiers, , France
Hématologie Clinique, CHU PONTCHAILLOU
Rennes, , France
Service Hématologie, Centre Hospitalier de Roubaix - Hôpital Victor Provo
Roubaix, , France
Service Hématologie, UNIVERSITE DE ROUEN, CENTRE HENRI BECQUEREL
Rouen, , France
Service Hématologie, CH YVES LE FOLL
Saint-Brieuc, , France
Service Hématologie, Institut Curie - Hôpital René HUGUENIN
Saint-Cloud, , France
Département d'Hématologie Clinique et Thérapie Cellulaire, Institut de Cancérologie Lucien Neuwirth
Saint-Priest-en-Jarez, , France
Hôpitaux Universitaires de Strasbourg
Strasbourg, , France
Institut Universitaire du Cancer
Toulouse, , France
Hématologie Clinique, CH DE BRETAGNE ATLANTIQUE
Vannes, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Romain GUIEZE, PhD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Ghesquieres H, Cherblanc F, Belot A, Micon S, Bouabdallah KK, Esnault C, Fornecker LM, Thokagevistk K, Bonjour M, Bijou F, Haioun C, Morineau N, Ysebaert L, Damaj G, Tessoulin B, Guidez S, Morschhauser F, Thieblemont C, Chauchet A, Gressin R, Jardin F, Fruchart C, Laboure G, Fouillet L, Lionne-Huyghe P, Bonnet A, Lebras L, Amorim S, Leyronnas C, Olivier G, Guieze R, Houot R, Launay V, Drenou B, Fitoussi O, Detourmignies L, Abraham J, Soussain C, Lachenal F, Pica GM, Fogarty P, Cony-Makhoul P, Bernier A, Le Guyader-Peyrou S, Monnereau A, Boissard F, Rossi C, Camus V. Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort. Blood Adv. 2024 Jan 23;8(2):296-308. doi: 10.1182/bloodadvances.2023010798.
Ghesquieres H, Rossi C, Cherblanc F, Le Guyader-Peyrou S, Bijou F, Sujobert P, Fabbro-Peray P, Bernier A, Belot A, Chartier L, Fornecker LM, Baldi I, Bouabdallah K, Laurent C, Oberic L, Morineau N, Le Gouill S, Morschhauser F, Haioun C, Damaj G, Guidez S, Laboure G, Fitoussi O, Lebras L, Gressin R, Salles G, Ysebaert L, Monnereau A. A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort. BMC Public Health. 2021 Mar 2;21(1):432. doi: 10.1186/s12889-021-10433-4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-A01332-53
Identifier Type: OTHER
Identifier Source: secondary_id
69HCL18_0352
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.